Immune cytopenia after paediatric haematopoietic cell transplantation

Czech version

Authors: M. Füssiová ¹; P. Švec ¹; J. Horáková ¹; I. Boďová ¹; J. Adamčáková ¹; D. Dóczyová ¹; T. Sýkora ¹; M. Pozdechová ¹; P. Sedláček ²; P. Rohoň ³; A. Kolenova ¹
Authors‘ workplace: Transplantačná jednotka kostnej drene, Klinika detskej hematológie a onkológie, Národný ústav detských chorôb, Bratislava, Slovensko ¹; Klinika dětské hematologie a onkologie 2. LF UK a FN Motol, Praha ²; Ústav lékařské genetiky a genomiky, LF MU a FN Brno ³
Published in: Transfuze Hematol. dnes,30, 2024, No. 3, p. 175-187.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2024prolekare.cz15

Overview

Immune cytopenia is a rare complication of haematopoietic stem cell transplantation. It is the result of immune system dysregulation after the reconstitution of donor haematopoiesis. Current recommendations and guidelines for the diagnosis and treatment of the disease in paediatric transplantation are unclear, based on knowledge about autoimmune cytopenia not associated with transplantation. Immune cytopenia associated with transplantation is usually more refractory and runs a prolonged course, conforming the different etiopathogenesis of the disease. Treatment includes a wide spectrum of approaches from observation to intensive management, especially in the case of coexistent other peri-transplantation complications. In addition to supportive treatment, patients may require modification of immunosuppression. Some cases may need treatment focused on removing plasma cells, auto- or alloantibodies from the bloodstream. We provide a comprehensive review of the pathophysiology, treatment and prognosis of post-transplant immune cytopenia in children, and we present our cohort of such patients.

Keywords:

haematopoietic cell transplantation – immune-mediated cytopenia in childhood – immune dysregulation – modification of immunosuppression – cohort of patients with immune cytopenia

Sources

1. Hwang-Bo S, Kim SK, Lee JW, et al. Treatment and response of autoimmune cytopenia occurring after allogeneic hematopoietic cell transplantation in children. Blood Res. 2017; 52 (2): 119–124.

2. Szanto CL, Langenhorst J, de Koning C, et al. Predictors for autoimmune cytopenias after allogeneic hematopoietic cell transplantation in children. Biol Blood Marrow Transplant. 2020; 26 (1): 114–122.

3. Neely JA, Dvorak CC, Pantell MS, Melton A, Huang JN, Shimano KA. Autoimmune cytopenias in pediatric hematopoietic cell transplant patients. Front Pediatr. 2019; 7: 171.

4. Galvin RT, Cao Q, Miller WP, Knight-Perry J, Smith AR, Ebens CL. Characterizing immune-mediated cytopenias after allogeneic hematopoietic cell transplantation for pediatric nonmalignant disorders. Transplant Cell Ther. 2021; 27 (4): 316.e1–316.e8.

5. Baur K, Buser AS, Infanti L, Halter JP, Passweg JR, Holbro A. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematol. 2021; 8 (3): e229–e239.

6. Styczyński J, Gągola K, Marjańska A. Autoimmune cytopenias complicating hematopoietic cell transplantation. Acta Haematol Pol. 2021; 52 (4): 257–262.

7. Even-Or E, Schejter YD, NaserEddin A, Zaidman I, Shadur B, Stepensky P. Autoimmune cytopenias post hematopoietic stem cell transplantation in pediatric patients with osteopetrosis and other nonmalignant diseases. Front Immunol. 2022; 13: 13: 879994.

8. Koo J, Giller RH, Quinones R, McKinney CM, Verneris MR, Knight-Perry J. Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: Response to therapy and late effects. Pediatr Blood Cancer. 2020; 67 (9): e28591.

9. Holbro A. Autoimmune hemolytic diseases-section 2 management of immune cytopenias after allogeneic stem cell transplantation. HemaSphere (Educational Updates in Hematology Book). 2020; 4 (S2).

10. Michniacki TF, Ebens CL, Choi SW. Immune-mediated cytopenias after hematopoietic cell transplantation: pathophysiology, clinical manifestations, diagnosis, and treatment strategies. Curr Oncol Rep. 2019; 21 (10): 87.

11. Deambrosis D, Lum SH, Hum RM, et al. Immune cytopenia post-cord transplant in Hurler syndrome is a forme fruste of graft rejection. Blood Adv. 2019; 3 (4): 570–574.

12. González-Vicent M, Sanz J, Fuster JL, et al. Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH). Transfus Med Rev. 2018; 32 (3): 179–185.

13. Kruizinga MD, van Tol MJD, Bekker V, et al. Risk factors, treatment, and immune dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients. Biol Blood Marrow Transplant. 2018; 24 (4): 772–778.

14. Spadea M, Saglio F, Ceolin V, et al. Immune-mediated cytopenias (IMCs) after HSCT for pediatric non-malignant disorders: epidemiology, risk factors, pathogenesis, and treatment. Eur J Pediatr. 2023; 182 (6): 2471–2483.

15. Miller PDE, Snowden JA, Peffault De Latour R, et al. Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2020; 55: 441–451.

16. Buxbaum NP, Pavletic SZ. Autoimmunity following allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020; 11: 2017.

17. Aladjidi N, Jutand MA, Beaubois C, et al. Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. Pediatr Blood Cancer. 2017; 64 (12): e26683.

18. Ware R.E. OS, AC. Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis. – UpToDate. 2023. https: //www.uptodate.com/contents/ autoimmune-hemolytic-anemia-aiha-in- children-classification-clinical-features-and- diagnosis?search=AIHA%20in%20children& source=search_result&selectedTitle=1%7E1 50&usage_type=default&display_rank=1. 2023.

19. Coates T.D. NP, Newburger P, Rosmarin A.G. Immune neutropenia. UpToDate. 2023. https: //www.uptodate.com/contents/immune- neutropenia?search=autoimmune%20neutropenia%20in%20children&source=search_result&selectedTitle=1~70&usage_type=default&display_rank=1

20. Bussel j.B., O’Brien S., Armsby C. Immune thrombocytopenia (ITP) in children: Initial management. UpToDate. 2024. https: //www.uptodate. com/contents/immune-thrombocytopenia-itp-in-children-initial-management?search=immune-thrombocytopenia-itp-in-children-initial-management&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1

21. Migdady Y, Pang Y, Kalsi SS, Childs R, Arai S. Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics. Blood Adv. 2022; 6 (8): 2707–2721.

22. Hess J, Su L, Nizzi F, et al. Successful treatment of severe refractory autoimmune hemolytic anemia after hematopoietic stem cell transplant with abatacept. Transfusion (Paris). 2018; 58 (9): 2122–2127.

23. Holbro A, Passweg JR. Management of hemolytic anemia following allogeneic stem cell transplantation. Hematol Am Soc Hematol Educ Program. 2015 (1): 378–384.

24. Hsu WY, Chiou SS, Liao YM, et al. Successful management of multilineage autoimmune cytopenia complicated with severe infection and deep vein thrombosis in a patient with Hodgkin lymphoma post-autologous hematopoietic stem cell transplantation. Pediatr Transplant. 2016; 20 (1): 168–171.

25. Lum SH, Selvarajah S, Deya-Martinez A, et al. Outcome of autoimmune cytopenia after hematopoietic cell transplantation in primary immunodeficiency. J Allergy Clin Immunol. 2020; 146: 406–416.

26. Neunert CE, Despotovic JM. Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature. Pediatr Blood Cancer. 2019; 66 (4): e27 569.

27. Gupta AO, Jan Boelens J, Ebens CL, et al. Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. Bone Marrow Transplant. 2021; 56 (6): 1238.

28. Bohgaki T, Atsumi T, Koike T. Autoimmune disease after autologous hematopoietic stem cell transplantation. Autoimmun Rev. 2008; 7 (3): 198–203.

29. Hequet O, Salles G, Ketterer N, et al. Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. Bone Marrow Transplant. 2003; 32 (1): 89–95.

30. Driouk L, Schmitt R, Peters A, et al. Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature. Molec Cell Pediatrics. 2021; 8 (1): 1–7.

31. Hosoba S, Jaye DL, Cohen C, Roback JD, Waller EK. Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion (Paris). 2015; 55 (2): 259–264.

32. Chewning JH, Aban I, Haines HL, Brown R, Buchanan HH, Goldman FD. Immune-mediated cytopenia in pediatric primary immune deficiency patients following HSCT. Bone Marrow Transplantation. 2017; 52 (11): 1571–1574.

33. Khalil A, Zaidman I, Bergman R, Elhasid R, Ben-Arush MW. Autoimmune complications after hematopoietic stem cell transplantation in children with nonmalignant disorders. Sci World J. 2014. 2014: 581657.

34. Faraci M, Zecca M, Pillon M, et al. Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. Biol Blood Marrow Transplant. 2014; 20 (2): 272–278.

35. Feketeová J. Autoimunitná hemolytická anémia u detí – diagnosticko-terapeutický štandard. Ministerstvo zdravotníctva Slovenskej republiky, 2020.

36. Corbacioglu S, Kernan NA, Pagliuca A, Ryan RJ, Tappe W, Richardson PG. Incidence of anicteric veno-occlusive disease/sinusoidal obstruction syndrome and outcomes with defibrotide following hematopoietic cell transplantation in adult and pediatric patients. Biol Blood Marrow Transplant. 2020; 26 (7): 1342–1349.

37. Kleinman S, Silvergleid A, Tirnauer J S. Refractoriness to platelet transfusion therapy – UpToDate. 2021. https: //www.uptodate.com/con- tents/refractoriness-to-platelet-transfusion- therapy.

38. Mahadeo KM, Bajwa R, Abdel-Azim H, et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 2020; 7 (1): e61–e72.

39. Rebulla P. Formulae for the definition of refractoriness to platelet transfusion. Transfus Med. 1993; 3 (1): 91–92.

40. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness-practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015; 171 (3): 297–305.

41. Bento L, Canaro M, Bastida JM, Sampol A. Thrombocytopenia and therapeutic strategies after allogeneic hematopoietic stem cell transplantation. J Clin Med. 2022; 11 (5): 1364.

42. Moosavi MM, Duncan A, Stowell SR, Roback JD, Sullivan HC. Passenger lymphocyte syndrome; a review of the diagnosis, treatment, and proposed detection protocol. Transfus Med Rev. 2020; 34 (3): 178–187.

43. Schuetz C, Hoenig M, Moshous D, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018; 2 (19): 2550–2553.

44. Seidel MG. Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs). Hematol: Am Soc Hematol Educ Program. 2020 (1): 673–679.

45. Ruan Y, Cao W, Luo T, et al. Avatrombopag for the treatment of thrombocytopenia in children’s patients following allogeneic hematopoietic stem-cell transplantation: A pilot study. Front Pediatr. 2023; 11: 1099372.

46. Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017; 130 (21): 2243–2250.

47. Matsuoka KI, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013; 5 (179): 179ra43.

48. Tahvildari M, Dana R. Low dose interleukin-2 therapy in transplantation, autoimmunity and inflammatory diseases. J Immunol. 2019; 203 (11): 2749.

49. Graßhoff H, Comdühr S, Monne LR, et al. Low-dose IL-2 therapy in autoimmune and rheumatic diseases. Front Immunol. 2021; 12: 648 408.

50. Worel N. ABO-mismatched allogeneic hematopoietic stem cell transplantation. Transfusion Med Hemotherapy. 2016; 43 (1): 3.

PODIEL AUTOROV NA RUKOPISE

FM – príprava rukopisu

ŠP, HJ, BI, AJ, DD, ST, PM, SP, RP, KA – korekcia a revízia rukopisu

ČESTNÉ VYHLÁSENIE

Prácu podporuje Projekt Národní ústav pro výzkum rakoviny (Program EXCELES, ID: LX22NPO5102) – Financováno Evropskou unií – Next Generation EU. Autori práce vyhlasujú, že vznik ani publikácia článku neboli podporené žiadnou farmaceutickou firmou. Autori nemajú v súvislosti s témou článku žiadny konflikt záujmov.

Do redakce doručené dne: 29. 4. 2024.

Přijato po recenzi dne: 29. 5. 2024.

MUDr. Füssiová Mária

Transplantačná jednotka kostnej drene

KDHaO NÚDCH

Limbová 1, 831 01 Bratislava

e-mail: fussiova.maria@gmail.com